Stocks to buy in 2026 for long term: Dr Lal PathLabs, IDFC First Bank among 5 stocks that could give 10-30% return

Read post on economictimes.indiatimes.com

Nuvama has reiterated its 'Buy' rating on Dr Lal PathLabs and raised the target price to Rs 2,140 from Rs 1,900, implying a potential upside of 21% from the current market price of Rs 1,756.